Results 131 to 140 of about 21,694,813 (356)

Why 90% of clinical drug development fails and how to improve it?

Acta Pharmaceutica Sinica B, 2022
D. Sun, W. Gao, Hongxiang Hu, S. Zhou
semanticscholar   +1 more source

Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and Simulation

CPT: Pharmacometrics & Systems Pharmacology, 2019
The use of computational models in drug development has grown during the past decade. These model‐informed drug development (MIDD) approaches can inform a variety of drug development and regulatory decisions.
Colleen Kuemmel, Yuching Yang, Xinyuan Zhang, J. Florian, Hao Zhu, M. Tegenge, Shiew-Mei Huang, Yaning Wang, T. Morrison, I. Zineh   +9 more
semanticscholar   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186

Journal for ImmunoTherapy of Cancer, 2022
Ying Zhu, Danielle E Dettling, Eilene Kwok, Lucy Quach, Aakash Datt, Jeremiah D Degenhardt, Anand Panchal, Pui Seto, Jessica L Krakow, Russell Wall, Brian J Hillier, Maia Vinogradova, Robert B DuBridge, Chad May   +13 more
doaj   +1 more source

Cytokines Driven Anti-Inflammatory and Anti-Psoriasis Like Efficacies of Nutraceutical Sea Buckthorn (Hippophae rhamnoides) Oil

Frontiers in Pharmacology, 2019
Psoriasis is a chronic inflammatory skin disease characterized by circumscribed, red, thickened plaques with overlying silvery white scales. It is associated with the release of pro-inflammatory mediators that lead to the development of edema and ...
Acharya Balkrishna, Acharya Balkrishna, Sachin Shridhar Sakat, Kheemraj Joshi, Kamal Joshi, Vinay Sharma, Ravikant Ranjan, Kunal Bhattacharya, Anurag Varshney, Anurag Varshney   +9 more
doaj   +1 more source

The druggable genome and support for target identification and validation in drug development

Science Translational Medicine, 2016
The druggable genome and genome-wide association study data reveal new drug development and repurposing opportunities. An organized way to drug the genome Many drugs that are already approved for specific diseases have known protein targets, which may be
C. Finan, A. Gaulton, Felix A. Kruger, R. Lumbers, T. Shah, J. Engmann, L. Galver, Ryan M. Kelley, Anneli Karlsson, Rita Santos, John P. Overington, A. Hingorani, J. Casas   +12 more
semanticscholar   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide

Journal of Hematology & Oncology, 2018
Background Chimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy.
Erhao Zhang, Jieyi Gu, Jianpeng Xue, Chenyu Lin, Chen Liu, Mengwei Li, Jingchao Hao, Sarra Setrerrahmane, Xiaowei Chi, Weiyan Qi, Jialiang Hu, Hanmei Xu   +11 more
doaj   +1 more source

Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs [PDF]

, 2017
Kojiro Maeda, Masayuki Kaneko, Mamoru Narukawa, Teruyo Arato   +3 more
openalex   +1 more source

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

Alzheimer's Research & Therapy, 2014
Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist.
J. Cummings, Travis Morstorf, K. Zhong
semanticscholar   +1 more source